Hypopharyngeal Cancer - Pipeline Review, H2 2020

September 2020 | 495 pages | ID: H6BE6B3D815EN
Global Markets Direct

Abstracts

Hypopharyngeal Cancer - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypopharyngeal Cancer - Pipeline Review, H2 2020, provides an overview of the Hypopharyngeal Cancer (Oncology) pipeline landscape.
Hypopharyngeal cancer is a term used for tumors of a subsite of the upper aerodigestive tract, and like most other subsite designations, the distinction is anatomic rather than pathophysiologic within the group of head and neck malignancies. The hypopharynx is the region between the oropharynx above (at the level of the hyoid bone) and the esophageal inlet below (at the lower end of the cricoid cartilage). Embryologically, the larynx interjects into the hypopharynx anteriorly and is therefore considered a separate structure.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypopharyngeal Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hypopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hypopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Phase 0 stages are 5, 5, 10 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Hypopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hypopharyngeal Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Hypopharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hypopharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hypopharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hypopharyngeal Cancer (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hypopharyngeal Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hypopharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Hypopharyngeal Cancer - Overview
Hypopharyngeal Cancer - Therapeutics Development
Hypopharyngeal Cancer - Therapeutics Assessment
Hypopharyngeal Cancer - Companies Involved in Therapeutics Development
Hypopharyngeal Cancer - Drug Profiles
Hypopharyngeal Cancer - Dormant Projects
Hypopharyngeal Cancer - Discontinued Products
Hypopharyngeal Cancer - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Hypopharyngeal Cancer, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Hypopharyngeal Cancer - Pipeline by Ascenta Therapeutics Inc, H2 2020
Hypopharyngeal Cancer - Pipeline by AstraZeneca Plc, H2 2020
Hypopharyngeal Cancer - Pipeline by Biomimetix JV LLC, H2 2020
Hypopharyngeal Cancer - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
Hypopharyngeal Cancer - Pipeline by Eisai Co Ltd, H2 2020
Hypopharyngeal Cancer - Pipeline by GlaxoSmithKline Plc, H2 2020
Hypopharyngeal Cancer - Pipeline by Incyte Corp, H2 2020
Hypopharyngeal Cancer - Pipeline by Innate Pharma SA, H2 2020
Hypopharyngeal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2020
Hypopharyngeal Cancer - Pipeline by Merck & Co Inc, H2 2020
Hypopharyngeal Cancer - Pipeline by Moderna Inc, H2 2020
Hypopharyngeal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2020
Hypopharyngeal Cancer - Dormant Projects, H2 2020
Hypopharyngeal Cancer - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hypopharyngeal Cancer, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Ascenta Therapeutics Inc
AstraZeneca Plc
Biomimetix JV LLC
Boehringer Ingelheim International GmbH
Eisai Co Ltd
GlaxoSmithKline Plc
Incyte Corp
Innate Pharma SA
Jiangsu Hengrui Medicine Co Ltd
Merck & Co Inc
Moderna Inc
Ono Pharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shionogi & Co Ltd
VasGene Therapeutics Inc
Verastem Inc